Klin Farmakol Farm. 2009;23(4):194-197

Sitagliptin

Ondřej Krystyník
II. interní klinika, FN a LF UP Olomouc

Sitagliptin is an oral antidiabetic incretin-based drug. It is a specific inhibitor of DPP-4 (dipeptidyl peptidase-4), which regulates the

degradation and the bioactivity of native GLP-1 (glucagon-like peptide – 1) and GIP (glucose-dependent insulinotropic polypeptide).

Sitagliptin is characterized by low incidence of hypoglycemia during the therapy. Sitagliptin reduces mean HbA1c and has a neutral

inpact on body weight. Sitagliptin is generally well tolerated, with no significant side effects. Sitagliptin is being used in combination

with metformin and thiazonlidindiones. In experimental studies sitagliptin inhibits apoptosis of islets β-cells and stimulates their proliferation,

which results in increasing of β-cell mass.

Keywords: Sitagliptin, DPP-4 inhibitors, incretin hormones, GLP-1, GIP, type 2 diabetes mellitus

Published: May 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krystyník O. Sitagliptin. Klin Farmakol Farm. 2009;23(4):194-197.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ahrén B. What mediates the benefits associated with dipeptidyl peptidase-IV inhibition? Diabetologia 2008; 48: 605-607. Go to original source... Go to PubMed...
    2. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes. The Journal of the American Medical Association 2007; 298(2): 194-206. Go to original source... Go to PubMed...
    3. Drucker DJ. The biology of incretin hormones. Cell Metabolism 2006; 3: 153-165. Go to original source... Go to PubMed...
    4. Drucker DJ. The role of gut hormones in glucose homeostasis. The Journal of Clinical Investigation 2007; 117: 24-32. Go to original source... Go to PubMed...
    5. Elrick H. Plasma insulin response to oral and intravenous glucose administration. Journal of Clinical Endocrinology & Metabolism 1964; 24: 1076-1082. Go to original source... Go to PubMed...
    6. Gilbert MP, Pratley RE. Efficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus. European Journal of Internal Medicine 2009; 20: S309-S318. Go to original source... Go to PubMed...
    7. Kendall DM, Cuddihy RM, Bergenstal RM. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. The American Journal of Medicine 2009; 122: S37-S50. Go to original source... Go to PubMed...
    8. Kotačková L, Balážiová E, Šedo A. Expression Pattern of Dipeptidyl Peptidase IV Activity and/or Structure Homologues in Cancer. Folia Biologica 2009; 55: 77-84. Go to PubMed...
    9. Kvapil M. Sitagliptin. Remedia 2008; 18: S4-S10. Go to original source...
    10. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nature Reviews Endocrinology 2009; 5: 262-269. Go to original source... Go to PubMed...
    11. Mu J, Woods J, Zhou Y, et al. Chronic inhibition of dipeptidyl peptidase-4 with sitagliptin analog preserves pancreatic b-cell mass and fiction in a rodent model of type 2 diabetes. Diabetes 2006; 55: 1695-1704. Go to original source... Go to PubMed...
    12. Nauck MA, Heimesaat MM, Řrskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. The Journal of Clinical Investigation 1993; 91: 301-307. Go to original source... Go to PubMed...
    13. Nauck MA, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46-52. Go to original source... Go to PubMed...
    14. Nauck MA. Unraveling the Science of Incretin Biology. European Journal of Internal Medicine 2009; 20: S303-S308. Go to original source... Go to PubMed...
    15. Riche DM, East HE, Dale KM. Impact of Sitagliptin on markers of â-cell function: a meta-analysis. The American Journal of the Medical Sciences 2009; 337: 1-8. Go to original source... Go to PubMed...
    16. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vascular Health and Risk Management 2008; 4: 753-768. Go to original source... Go to PubMed...
    17. Souhrn údajů o přípravku Januvia (2008).

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.